1. ALLA AKTIER
  2. NYHETER
  3. CINCLUS PHARMA

Cinclus Pharma

Nyheter Cinclus Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Cinclus Pharma to participate in upcoming investor conferences

Cinclus Pharma Holding AB (publ) announces today that the company’s management will participate in the following investor conferences during the spring of 2026:

Redeye Healthcare Day
Format: Presentation (in Swedish)
Date and time: April 14, 10.10-10-30 CET
Location: Stockholm
Webcast: https://www.redeye.se/events/1145882/redeye-healthcare-day-2026
 
Van Lanschot Kempen Life Sciences Conference
Format: 1x1 meetings
Date: April 15-16
Location: Amsterdam
 
Jefferies Global Healthcare Conference
Format: Presentation and 1x1 meetings
Date: June 2-4
Location: New York
 
To request a meeting or for more details about the conferences, please reach out to your institutional contact at Redeye, Van Lanschot Kempen and Jefferies.

For additional information, please contact:

Christer Ahlberg, CEO
Phone: +46 70 675 33 30
e-mail: christer.ahlberg@cincluspharma.com

Henrik Vikström, IR
Phone: +46 70 952 80 06
e-mail: henrik.vikström@cincluspharma.com

About Cinclus Pharma

Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. The first Phase III study commenced in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com.

Attachments

Cinclus Pharma to participate in upcoming investor conferences

Datum 2026-03-31, kl 08:00
Källa MFN
Bifogade filer
Cinclus Pharma to participate in upcoming investor conferences